ALTSTATION.IO

AbbVie Inc. (ABBV) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$223.97

Change

+2.26%

Market Cap

$395.84B

Avg Volume

6.4M

Company Overview

AbbVie Inc. (ABBV) is a biopharmaceutical company based in North Chicago, specializing in the research, development, manufacturing, and commercialization of various medicines and therapies. Their product lineup includes Humira, a leading treatment for autoimmune and intestinal diseases, and newer options like Skyrizi and Rinvoq for autoimmune disorders. They also produce cancer therapies such as Imbruvica and Venclexta, along with treatments for neurological conditions like Parkinson’s disease and schizophrenia. Their customer base spans healthcare providers and patients globally.

AbbVie is a market leader in several therapeutic areas, particularly autoimmune and oncology treatments. Their strong position is bolstered by a diverse portfolio and continued investment in R&D. However, they face pressures from generic competitors and patent expirations, particularly with Humira, which has seen significant revenue contributions. Competitors like Amgen and Pfizer are consistently looking to capture market share, especially in biosimilars and alternative therapies, creating an increasingly competitive environment.

Currently, AbbVie is transitioning as key patents expire, shifting focus onto newer drugs like Rinvoq and Skyrizi to sustain growth. The company has restructured its development pipeline and is investing heavily in emerging areas like neuroscience and oncology, aiming for long-term sustainability. Recent acquisitions, such as Allergan, have expanded their product offerings significantly, positioning them well for future growth despite pressures from existing product sales declines.

Key Financials

Market Cap

$395.84B

Revenue

$61.16B

EBITDA

$29.42B

Gross Margin

71.6%

Profit Margin

6.9%

Revenue Growth

10.0%

Total Cash

$5.67B

Total Debt

$68.85B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

94.50

Forward P/E

14.09

Beta

0.33

52-Week High

$244.81

52-Week Low

$164.39

EPS

$2.37

50-Day Avg

$224.14

200-Day Avg

$209.40

Price/Book

-149.81

Technical Analysis

AbbVie Inc. (ABBV) has shown a strong uptrend over the past 52 weeks, with a significant increase of 21.3%, currently priced at $223.97. Key support is identified around $180, which held during multiple pullbacks in early 2023. Resistance appears at approximately $240, where the stock faced selling pressure in January and February. Over the last few weeks, ABBV has exhibited consolidation near the $220 level, indicating potential indecision among investors as it approaches previous highs. The current price is positioned favorably within the 52-week range, reflecting a robust upward movement and suggesting potential for continued bullish sentiment as it remains above key support levels. The recent momentum indicates a battle between buyers and sellers, with the price settling into a potentially advantageous breakout scenario.

Recent News and Developments

Here’s a summary of the latest news and developments for AbbVie Inc

(ABBV) stock in the past week, from January 31, 2026, to February 7, 2026:

1. AbbVie Exceeds Q4 2025 Earnings and Revenue Estimates, Provides Upbeat 2026 Outlook

AbbVie reported strong fourth-quarter and full-year 2025 financial results on February 4, 2026, surpassing analysts’ expectations for both earnings per share (EPS) and revenue. The company announced an adjusted Q4 EPS of $2.71, beating the consensus estimate of $2.65, and generated $16.62 billion in revenue, exceeding the anticipated $16.39 billion. Looking ahead, AbbVie issued an optimistic adjusted diluted EPS guidance for the full-year 2026, projecting between $14.37 and $14.57, which is above the analyst consensus of $14.22.

2. Immunology Portfolio Drives Growth, Regulatory Filings for Rinvoq in Vitiligo Submitted

AbbVie’s immunology drugs, Skyrizi and Rinvoq, were key drivers of growth in the fourth quarter of 2025, demonstrating double-digit increases and outperforming sales projections. In regulatory news, AbbVie announced the submission of applications to both the FDA and EMA for Rinvoq (upadacitinib) for the treatment of vitiligo. This potential expanded indication for Rinvoq could offer an additional avenue for future growth, building on the success of its immunology portfolio.

Market Sentiment and Analyst Recommendations

Bull Case

AbbVie just beat Q4 earnings and revenue, with adjusted EPS of $2.71 versus $2.65 expected, and guided 2026 EPS to $14.37-$14.57 against consensus of $14.22. The immunology franchise is firing on all cylinders — Skyrizi and Rinvoq both posted double-digit growth and outperformed projections. The Rinvoq vitiligo filing with FDA and EMA opens a new indication in a dermatology market with limited competition, giving the company multiple expansion paths. At a P/E of 94.5x, the valuation looks expensive until you factor in the 10% revenue growth and the strength of their core pipeline. Analysts are overwhelmingly bullish with 27 buy ratings, and the $244.96 price target implies 9.5% upside from current levels. The stock’s 21.3% gain over 52 weeks shows institutional confidence, and consolidation near $220 sets up a potential breakout through the $240 resistance level.

Bear Case

The P/E of 94.5x is brutal for a mature pharma company, even with growth. The debt load sits at $68.85 billion against only $5.67 billion in cash, leaving limited flexibility for acquisitions or shareholder returns during downturns. Oncology and aesthetics segments are declining, which matters because those historically drove diversification away from immunology concentration risk. If Skyrizi or Rinvoq hit unexpected safety signals or competitive headwinds from newer biologics, the growth narrative collapses fast. The recent 3.8% post-earnings selloff despite a beat suggests institutional money isn’t fully convinced on the diversification story. UBS downgrading the price target from $240 to $230 signals that even bullish analysts are getting cautious on near-term momentum.

What to Watch

Monitor Q1 2026 earnings in late April for immunology segment growth rates — if Skyrizi or Rinvoq growth slows below double digits, the bull case weakens significantly. Track the FDA decision timeline on Rinvoq for vitiligo, which could be a 2026 catalyst if approved. Watch the $240 resistance level closely; a sustained breakout would confirm the uptrend, while a breakdown below $220 would signal a reversal. Keep tabs on debt reduction progress and free cash flow generation to justify the elevated valuation. Compare AbbVie’s immunology growth rates directly against competitors like Eli Lilly and Regeneron to assess whether ABBV is truly outperforming or just benefiting from sector tailwinds. Finally, monitor analyst sentiment shifts — if more firms follow UBS downward, that’s a red flag even if fundamentals stay solid.

Analyst Consensus

BUY

Based on 27 analyst opinions

Low Target

$184.00

Mean Target

$244.96

High Target

$289.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

May 01, 2026

EPS (Trailing)

$2.37

Dividend Yield

304.0%

Payout Ratio

278.0%

Frequently Asked Questions

Is ABBV a good stock to buy?

Analysts recommend buying AbbVie Inc. (ABBV) with a target price of $244.96, suggesting a potential upside from its current price of $223.97. The favorable forward P/E of 14.09 indicates strong earnings growth potential.

What is ABBV’s price target?

The analyst consensus sets AbbVie’s price target at $244.96. This target implies about a 10% upside from the current trading price of $223.97.

Does ABBV pay a dividend?

Yes, AbbVie offers a substantial dividend yield of 304.0%. This makes it an attractive option for income-focused investors.

What is the P/E ratio for ABBV?

AbbVie has a high P/E ratio of 94.50, reflecting strong market expectations for growth. However, its forward P/E of 14.09 is much more appealing and suggests solid earnings ahead.

What has been ABBV’s stock price range over the past year?

The stock has traded between $164.39 and $244.81 in the last 52 weeks. This range indicates volatility, but it also signals opportunity for trading at lower points.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.